---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-025329"
form_type: "8-K"
ticker: "ADCT"
cik: "0001771910"
company_name: "ADC Therapeutics SA"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:28:03.203197+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ADC Therapeutics Q1 net loss narrows to $38.6M; ZYNLONTA revenue $17.4M, LOTIS-7 shows 95.5% ORR

## Summary
- Q1 product revenue $17.4M vs $17.8M YoY; license revenue $5.6M including $5M Canadian milestone.
- Net loss $38.6M ($0.36/sh) vs $46.6M ($0.56); adjusted net loss $24.0M ($0.22).
- Cash $194.7M at March 31; runway expected into H2 2026.
- LOTIS-7 (ZYNLONTA+glofitamab) enrolled 40 patients; abstract shows 95.5% ORR, 90.9% CR.
- LOTIS-5 confirmatory trial on track for PFS events by end of 2025; ADCT-602 discontinued.

## SEC filing metadata
- accession: 0001628280-25-025329
- form_type: 8-K
- ticker: ADCT
- cik: 0001771910
- company_name: ADC Therapeutics SA
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1771910/000162828025025329/0001628280-25-025329-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1771910/000162828025025329/adc-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-025329
- JSON: https://secwatch.observer/filing/0001628280-25-025329.json
- Plain text: https://secwatch.observer/filing/0001628280-25-025329.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.